Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics (GLUE) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

• GLUE last traded at $10.63, -1.21% on the day.
• Monte Rosa Therapeutics: P/E -4.9, revenue $28.73M over the last four quarters.
• Over the past year GLUE returned -18.29%; year to date -32.21%.

Updated 2026-11-02 18:01 UTC